Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
… EGFR mutations with clinical factors predictive of response to erlotinib or gefitinib, we found
that … with patients with EGFR L858R after treatment with erlotinib or gefitinib (P = 0.01). …
that … with patients with EGFR L858R after treatment with erlotinib or gefitinib (P = 0.01). …
[HTML][HTML] Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
… of adjuvant erlotinib or gefitinib delivery were recorded. Patients at MSKCC receive adjuvant
erlotinib or gefitinib by enrolling in phase 2 clinical trials, 24 , 25 or outside of a clinical trial. …
erlotinib or gefitinib by enrolling in phase 2 clinical trials, 24 , 25 or outside of a clinical trial. …
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib …
… and acquired clinical resistance to gefitinib and/or erlotinib … clinical trials, we evaluated the
disease course and associated clinical and molecular factors of patients enrolled on clinical …
disease course and associated clinical and molecular factors of patients enrolled on clinical …
[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
… We developed a clinical significance curve and risk-benefit contour to illustrate how the …
-Lung 7 to estimate the additional clinical benefit of afatinib versus gefitinib 5 and the results of …
-Lung 7 to estimate the additional clinical benefit of afatinib versus gefitinib 5 and the results of …
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR …
S Heon, BY Yeap, NI Lindeman, VA Joshi… - Clinical Cancer …, 2012 - AACR
… gefitinib or erlotinib significantly lowers the risk of CNS progression during the disease course
… Therefore, we retrieved information on the clinical presentation and course of our patients …
… Therefore, we retrieved information on the clinical presentation and course of our patients …
… of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
… kinase inhibitors, gefitinib and erlotinib, on … clinical presentation and course of our patients
with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib or erlotinib …
with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib or erlotinib …
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of …
… progression of disease after discontinuation of erlotinib or gefitinib in patients … resistance to
erlotinib or gefitinib, continued treatment with erlotinib or … Clinical course of individual patients …
erlotinib or gefitinib, continued treatment with erlotinib or … Clinical course of individual patients …
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
DB Costa, KSH Nguyen, BC Cho, LV Sequist… - Clinical cancer …, 2008 - AACR
… clinical course of 18 EGFR mutated NSCLC that were treated with gefitinib and, on resistance,
erlotinib… exon 19 deletions), and initial response to gefitinib 250 mg/d were consistent with …
erlotinib… exon 19 deletions), and initial response to gefitinib 250 mg/d were consistent with …
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection
A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa… - Lung cancer, 2011 - Elsevier
… the clinical course of patients with the longest three PFS (13.8, 12.4, and 11.6 months), gefitinib
was directly switched to erlotinib … In the clinical course of treatment with EGFR-TKIs, CNS …
was directly switched to erlotinib … In the clinical course of treatment with EGFR-TKIs, CNS …
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months
H Saito, S Murakami, T Kondo, F Oshita… - Oncology Research …, 2012 - karger.com
… The best overall tumor responses (complete response (CR), partial response (CR), stable
disease (SD), progressive disease (PD)) during the course of different treatment modalities …
disease (SD), progressive disease (PD)) during the course of different treatment modalities …
相关搜索
- cell lung cancer gefitinib or erlotinib
- adjuvant gefitinib distinct clinical course
- gefitinib erlotinib and afatinib clinical trials
- egfr kinase domain gefitinib or erlotinib
- deletion mutations gefitinib or erlotinib
- individual patient data gefitinib or erlotinib
- prospective assessment erlotinib or gefitinib
- gefitinib in patients study of erlotinib
- treatment with erlotinib clinical utility
- disease flare erlotinib or gefitinib
- evidence for disease control gefitinib failure
- second mutation gefitinib or erlotinib
- somatic egfr mutations gefitinib or erlotinib
- clinical course of patients
- prolonged survival gefitinib or erlotinib
- results of testing distinct clinical course